FDMT250117C15000
- 0.05
- 0.000.00%
4D Molecular Therapeutics Newsroom
Leerink Partners Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $27
4D Molecular Therapeutics Is Maintained at Outperform by Leerink Partners
Morgan Stanley Maintains Underweight on 4D Molecular Therapeutics, Lowers Price Target to $6
H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36
4D Molecular Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
Barclays Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)
BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $42
BMO Capital Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating, Cuts Target Price to $15
BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $46
4D Molecular Therapeutics Analyst Ratings
Morgan Stanley Initiates 4D Molecular Therapeutics(FDMT.US) With Sell Rating, Announces Target Price $8
Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $39
4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital
RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating
H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36
Barclays Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $45
Barclays Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
4D Molecular Therapeutics Analyst Ratings